Cost of sumatriptan

Feczko, Joe

doi:10.1016/0140-6736(92)90511-z

Search citation statements

Order By: Relevance

Paper Sections

Select...

Methods1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first article on the burden of migraine in the United States appeared in 1994 [10]. Articles on the cost of the first triptan began appearing in 1992 [11], with the first economic comparison of sumatriptan with nontriptan treatment appearing in Clinical Therapeutics in 1994 [12]. This was followed by tens of articles, published through the present, reporting different studies of the impact of triptans on direct and indirect costs and patient‐reported outcomes.…”

Section: Methodsmentioning

confidence: 99%

The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis

Hazard¹,

Munakata²,

Bigal³

et al. 2009

Value in Health

143

125

View full text Add to dashboard Cite

Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.

show abstract

Section: Methodsmentioning

confidence: 99%